covid-19 vaccine patient

COVID-19 Scan for Oct 28, 2021

Reading now: 896
www.cidrap.umn.edu

New monoclonal antibody sharply reduces risk of severe COVID outcomesThe monoclonal antibody sotrovimab reduced the risk of hospitalization or death from COVID-19 by 85% compared with placebo, according to an interim analysis of a phase 3 clinical trial published yesterday in the New England Journal of Medicine.In the double-blind, multicenter trial, non-hospitalized patients with symptomatic COVID-19 and at least one risk factor for disease progression were randomly assigned to receive either 500 milligrams of sotrovimab, a pan-sarbecovirus monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology, or placebo.

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA